# Eli Lilly and Company (LLY) — Q3-2018 Earnings Results

**Report date:** 2018-11-06 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/LLY/earnings/Q3-2018

## Post-Earnings Brief

### Headline

Eli Lilly Misses on EPS, Stock Down 3.85%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.39 | N/A | -2.03% |

### Management Commentary

**Tone:** Cautiously Optimistic

Management remains focused on innovation and future product pipelines. They acknowledged the current market pressures but are optimistic about future opportunities.

**Key quotes:**

> Management highlighted ongoing investments in research and development.

> They expressed confidence in long-term growth despite current challenges.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Eli Lilly's earnings report showed a slight miss on EPS, which contributed to a 3.85% decline in stock price. Investors may be concerned about the lack of revenue details and forward guidance, leading to uncertainty in the stock's near-term performance. The company's focus on R&D suggests a long-term strategy, but immediate reactions reflect caution among investors.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/LLY/earnings/Q3-2018_